Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABFRA:8LY +2.64%26 Buyback Yield % is -8.91 as of Aug. 15, 2026. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 724 Biotechnology companies, OncoZenge AB ranks better than 51.8% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for OncoZenge AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8LY vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, OncoZenge AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoZenge AB (FRA:8LY) has a Buyback Yield % of -8.91 as of Aug. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #349 out of 724 companies in the Biotechnology industry, placing it in the top 48.2%.
Is OncoZenge AB's Buyback Yield % too high?
OncoZenge AB's current Buyback Yield % is -8.91. Based on the distribution chart, OncoZenge AB ranks #349 out of 724 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #349 out of 724 companies for Buyback Yield %. This puts OncoZenge AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current Buyback Yield % is -8.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current Buyback Yield % of -8.91. The current Buyback Yield % is -8.91. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current Buyback Yield % is -8.91 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score
Get the complete analysis for FRA:8LY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8LY has been successfully added to your 
